Aripiborg

 

 

 

Aripiborg

Aripiprazole 15 mg

Indications:

Aripiborg 15 mg tablet is indicated for the treatment of schizophrenia in adults and in adolescents 15 years and older.

Aripiborg 15 mg tablet is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode

in patients who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.

Dosage and administration:

– Adults:

  • Schizophrenia: The recommended starting dose for Aripiborg tablets is 10 or 15 mg/day with a maintenance dose of 15 mg/day administered on a once-a-day

schedule without regard to meals.

Aripiborg tablets is effective in a dose range of 10 to 30 mg/day. Enhanced efficacy at doses higher than a daily dose of 15 mg has not been demonstrated although

individual patients may benefit from a higher dose. The maximum daily dose should not exceed 30 mg.

  • Manic episodes: The recommended starting dose for Aripiborg tablets is 15 mg administered on a once-a-day schedule without regard to meals as monotherapy

or combination therapy. Some patients may benefit from a higher dose. The maximum daily dose should not exceed 30 mg.

  • Recurrence prevention of manic episodes in Bipolar I Disorder: For preventing recurrence of manic episodes in patients who have been receiving aripiprazole

as monotherapy or combination therapy, continue therapy at the same dose. Adjustments of daily dosage, including dose reduction should be considered on

the basis of clinical status.

– Pediatric population:

  • Schizophrenia in adolescents 15 years and older: the recommended dose for Aripiprazole tablets are 10 mg/day administered on a once-a-day schedule without

regard to meals. Treatment should be initiated at 2 mg for 2 days, titrated to 5 mg for 2 additional days to reach the recommended daily dose of 10 mg. When

appropriate, subsequent dose increases should be administered in 5 mg increments without exceeding the maximum daily dose of 30 mg.

  • Aripiborg tablets are effective in a dose range of 10 to 30 mg/day. Enhanced efficacy at doses higher than a daily dose of 10 mg has not been demonstrated in

adolescents although individual patients may benefit from a higher dose.

  • Aripiborg tablets are not recommended for use in patients below 15 years of age due to insufficient data on safety and efficacy.
  • Irritability associated with autistic disorder: the safety and efficacy of Aripiborg tablets in children and adolescents below 18 years of age have not yet been

Package and storage:

– Carton box containing a blister (PVC/Alu) of 10 tablets and insert leaflet.

– Store in cool and dry place at a temperature not exceeding 30 °C.

– Keep out of the reach of children.

– Do not use unless under physician supervision.

inquiry